Healthcare
TransMedics Group, Inc.(TMDX)
Live Price
Offline$78.79
+7.61% today
1Y Change
-36.23%
Window
Jun 20, 2025 โ Jun 18, 2026
- Market Cap
- $3.45B
- Revenue Growth
- +37.1%
- EPS Growth
- +423.4%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 20, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TransMedics Group, Inc. (TMDX) is a Healthcare stock with a market cap of $3.45B and listed on NASDAQ. The stock last traded around $78.79 and down 36.2% across the available one-year price window (Jun 20, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +37.1%, EPS growth of +423.4%, a dividend yield of 0.0%. What stands out right now is revenue +37.1%, EPS +423.4%, free cash flow +265.0% with operating margin 17.9% and ROIC 10.9%. Valuation is more restrained than many high-expectation growth names at P/E 18.0 and price/sales 5.7. Stock Foundry combines TMDX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+37.1% vs +7.6% peer median
Operating Margin
Near sector median
+17.9% vs +19.4% peer median
P/E
Below sector median
18.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on May 5, 2026 with an EPS surprise of -51.6% and a revenue surprise of -0.3%.
The operating story is still moving forward
Revenue is running at +37.1% and EPS at +423.4%, with operating margin around 17.9%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 30, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -10.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | -51.6% | -23.2% | -32.7% | -26.6% |
2026 Feb 24, 2026 | +39.0% | -4.3% | +7.4% | -20.9% |
2025 Oct 29, 2025 | +78.4% | +1.1% | -7.3% | +8.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TMDX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TMDX Max Drawdown
-58.76%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TMDX and SPY.
Company Overview
TransMedics Group, Inc.
NASDAQ Global Market
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
- Leadership
- Waleed H. Hassanein
- IPO Date
- May 2, 2019
- Employees
- 728
- Street Address
- 200 Minuteman Road
- Mailing
- Andover, MA, 01810
- Region
- Andover, MA, US
- Reporting Currency
- USD
- Investor Line
- 978 552 0900
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 18.0
- EV/EBITDA
- 23.1
- Price/Sales
- 5.7
- Price/Book
- 7.2
Growth
- Revenue
- +37.1%
- EPS
- +423.4%
- Free Cash Flow
- +265.0%
Profitability
- Gross Margin
- 59.9%
- Operating Margin
- 17.9%
- Net Margin
- 31.4%
- ROE
- 53.9%
- ROIC
- 10.9%
Balance Sheet
- Debt/Equity
- 0.99
- Current Ratio
- 7.14
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.